Skip to main content


Table 3 Eligibility criteria

From: Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response

Inclusion Criteria
• Diagnosis of MS according to the McDonald criteria 2010 and cranial MRI scan demonstrating white matter lesions attributable to MS within 5 years before signing the informed consent form (ICF)
• Age > 18 years
• Written informed consent to study participation
Exclusion Criteria
• Medical, psychiatric, cognitive, or other conditions that, in the Investigator’s opinion, compromise the patient’s ability to understand the patient information, to give informed consent, or to complete the study
• Any progressive form of MS
• Any condition that serves as a contraindication for alemtuzumab treatment
• Any disability acquired from trauma or another illness that could interfere with the evaluation of disability due to MS
• Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety or interfere with the interpretation of study results, e.g., current peptic ulcer disease or other conditions that may predispose to hemorrhage
• Significant autoimmune disease including but not limited to immune cytopenias, rheumatoid arthritis, systemic lupus erythematosus, other connective tissue disorders, vasculitis, inflammatory bowel disease, severe psoriasis
• Inability to undergo MRI with gadolinium administration